Oncotarget

Research Papers:

MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma

Cheng-Han Lin, Chen-Hsun Tsai, Ching-Tung Yeh, Jui-Lin Liang, Wan-Chun Hung, Forn-Chia Lin, Wei-Lun Chang, Hao-Yi Li, Yun-Chin Yao, Tai-I Hsu, Yu-Cheng Lee, Yi-Ching Wang, Bor-Shyang Sheu, Wu-Wei Lai, Marcus J. Calkins, Michael Hsiao and Pei-Jung Lu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:39680-39693. https://doi.org/10.18632/oncotarget.9444

Metrics: PDF 830 views  |   HTML 1311 views  |   ?  


Abstract

Cheng-Han Lin1,9,*, Chen-Hsun Tsai2,*, Ching-Tung Yeh1, Jui-Lin Liang1,3, Wan-Chun Hung1, Forn-Chia Lin4, Wei-Lun Chang1,5, Hao-Yi Li1, Yun-Chin Yao6, Tai-I Hsu2, Yu-Cheng Lee2, Yi-Ching Wang7, Bor-Shyang Sheu1,5, Wu-Wei Lai8, Marcus J. Calkins1, Michael Hsiao9, Pei-Jung Lu1,2

1Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan

2Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan

3Department of General Surgery, Chi-Mei Medical Center, Liouying, Tainan 736, Taiwan

4Department of Radiation Oncology, National Cheng Kung University Hospital, Tainan 704, Taiwan

5Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 704, Taiwan

6Clinical Medicine Research Center, National Cheng Kung University Hospital, Tainan 704, Taiwan

7Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan

8Department of Surgery Medicine, National Cheng Kung University Hospital, Tainan 704, Taiwan

9Genomics Research Center, Academia Sinica, Taipei 115, Taiwan

*These authors contributed equally to this work

Correspondence to:

Michael Hsiao, email: mhsiao@gate.sinica.edu.tw

Pei-Jung Lu, email: pjlu2190@mail.ncku.edu.tw

Keywords: miR-193a-5p, ERBB2, CCRT, esophageal squamous cell carcinoma, indicator

Received: October 16, 2015     Accepted: March 31, 2016     Published: May 18, 2016

ABSTRACT

Concurrent chemoradiation therapy (CCRT) is the predominant treatment in esophageal cancer, however resistance to therapy and tumor recurrence are exceedingly common. Elevated ERBB2/Her2 may be at least partially responsible for both the high rates of recurrence and resistance to CCRT. This receptor tyrosine kinase is upregulated in 10–20% of esophageal squamous cell carcinoma (ESCC) tissues, and amplification of ERBB2 has been correlated with poor prognosis in esophageal cancer. Tissues from 131 ESCC patients, along with cell and animal models of the disease were used to probe the underlying mechanisms by which ERBB2 upregulation occurs and causes negative outcomes in ESCC. We found that overexpression of ERBB2 inhibited radiosensitivity in vitro. Furthermore, miR-193a-5p reduced ERBB2 expression by directly targeting the 3’UTR. Increased miR-193a-5p enhanced radiosensitivity and inhibited tumorigenesis in vitro and in vivo. Additionally, low miR-193a-5p expression correlated with poor prognosis in ESCC patients, and ESCC patients with good CCRT response exhibited higher miR-193a-5p expression. Our data suggest that patients with high miR-193a-5p will likely benefit from CCRT treatment alone, however a combination of CCRT with Herceptin may be beneficial for patients with low miR-193a-5p expression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9444